Estimation of Intracellular Concentration of Stavudine Triphosphate in HIV-Infected Children Given a Reduced Dose of 0.5 Milligrams per Kilogram Twice Daily

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2013-12-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1128/AAC.01717-13PMID 24295968PMCID PMC3910857
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Poor Early Virologic Performance and Durability of Abacavir-based First-line Regimens for HIV-infected Children

  2013cited by this paper
• Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement.

  2012cited by this paper
• Pharmacokinetic and Pharmacodynamic Analysis of Efavirenz Dose Reduction Using an In Vitro–In Vivo Extrapolation Model

  2012cited by this paper
• High prevalence of lipoatrophy in pre-pubertal South African children on antiretroviral therapy: a cross-sectional study

  2012cited by this paper
• Bioequivalence of Dispersed Stavudine: Opened versus Closed Capsule Dosing

  2011cited by this paper
• In silico study supports the efficacy of a reduced dose regimen for stavudine.

  2011influential reference
• Pediatric HIV--a neglected disease?

  2011cited by this paper
• Relationship between HIV/Highly active antiretroviral therapy (HAART)-associated lipodystrophy syndrome and stavudine-triphosphate intracellular levels in patients with stavudine-based antiretroviral regimens.

  2010cited by this paper
• LIPODYSTROPHY SYNDROME IN HIV-INFECTED CHILDREN ON HAART.

  2009cited by this paper
• Author manuscript, published in "European Journal of Clinical Pharmacology 2007;63(11):1019-29" DOI: 10.1007/s00228-007-0337-x

  2009influential reference
• Stavudine plasma concentrations and lipoatrophy.

  2008cited by this paper
• Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study.

  2008cited by this paper
• Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment

  2007cited by this paper
• Age-related differences in the pharmacokinetics of stavudine in 272 children from birth to 16 years: a population analysis.

  2007influential reference
• The Impact of Reducing Stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients

  2006cited by this paper
• Reductions in Stavudine Dose Might Ameliorate Mitochondrial-Associated Complications Without Compromising Antiviral Activity

  2005cited by this paper
• Macrophage Tropism of HIV-1 Depends on Efficient Cellular dNTP Utilization by Reverse Transcriptase*

  2004cited by this paper
• Monitoring of didanosine and stavudine intracellular trisphosphorylated anabolite concentrations in HIV-infected patients

  2004influential reference
• CDC GROWTH CHARTS FOR THE UNITED STATES: METHODS AND DEVELOPMENT 2000

  2002cited by this paper
• 2000 CDC Growth Charts for the United States: methods and development.

  2002cited by this paper
• Increased Turnover of T Lymphocytes in HIV-1 Infection and Its Reduction by Antiretroviral Therapy

  2001cited by this paper
• Determination of Dosing Guidelines for Stavudine (2′,3′-Didehydro-3′-Deoxythymidine) in Children with Human Immunodeficiency Virus Infection

  2001cited by this paper
• Impact of Stavudine Phenotype and Thymidine Analogues Mutations on Viral Response to Stavudine plus Lamivudine in Altis 2 Anrs Trial

  2001cited by this paper
• A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients

  2000cited by this paper
• Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans

  1999cited by this paper
• Involvement of multiple transporters in the oral absorption of nucleoside analogues.

  1999cited by this paper
• Safety and antiretroviral effects of combined didanosine and stavudine therapy in HIV-infected individuals with CD4 counts of 200 to 500 cells/mm3.

  1999cited by this paper
• Genotypic and phenotypic resistance to stavudine after long-term monotherapy. BMS-020 Spanish Study Group.

  1998cited by this paper
• Genotypic and Phenotypic Resistance to Stavudine after Long-Term Monotherapy

  1998cited by this paper
• Clinical Efficacy of Monotherapy with Stavudine Compared with Zidovudine in HIV-Infected, Zidovudine-Experienced Patients

  1997cited by this paper
• Dose-related activity of stavudine in patients infected with human immunodeficiency virus.

  1995cited by this paper
• Design and implementation of the stavudine parallel-track program.

  1995cited by this paper
• A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection.

  1995cited by this paper
• Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex.

  1992cited by this paper
• Nucleoside and nucleobase transport in animal cells.

  1988cited by this paper

• Physiologically-based pharmacokinetic modeling to inform dosing regimens and routes of administration of rifampicin and colistin combination against Acinetobacter baumannii.

  2023cites this paper
• Physiologically based pharmacokinetic‐pharmacodynamic evaluation of meropenem plus fosfomycin in paediatrics

  2020cites this paper
• Physiologically‐based pharmacokinetics of ziprasidone in pregnant women

  2019cites this paper
• Can We Improve Stavudine's Safety Profile in Children? Pharmacokinetics of Intracellular Stavudine Triphosphate with Reduced Dosing

  2018cites this paper
• Complete Phase-Out Stavudine Based Regimens in the Treatment of HIV-Infection: is it True That Stavudine Hasn’t Any Benefit Today? A Review

  2017influential citation
• Liquid chromatography–mass spectrometry methods for the intracellular determination of drugs and their metabolites: a focus on antiviral drugs

  2017cites this paper
• Nucleotide Reverse Transcriptase Inhibitors: A Thorough Review, Present Status and Future Perspective as HIV Therapeutics.

  2017cites this paper
• Effect of reducing the paediatric stavudine dose by half: a physiologically-based pharmacokinetic model.

  2015cites this paper
• Predicting Pediatric Age-Matched Weight and Body Mass Index

  2014cites this paper